Imexpharm

Imexpharm Operating Cash Flow

The Operating Cash Flow of Imexpharm (IMP.VN) as of Oct 26, 2026 is 54.17 B VND. In the previous year, Operating Cash Flow was 216.27 B VND — a change of -74.95% (lower).

Operating Cash Flow

54.17 BVND

YoY

-74.95%

Last updated:

Operating Cash Flow of Imexpharm is 2025 54.17 B VND. Operating Cash Flow of Imexpharm was 2024 216.27 B VND. It decreases by -74.95% lower compared to the previous year.

The Imexpharm Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
132.09 B VND
Jan 1, 2019
66.59 B VND
Jan 1, 2020
73.15 B VND
Jan 1, 2021
234.88 B VND
Jan 1, 2022
378.60 B VND
Jan 1, 2023
-40.47 B VND
Jan 1, 2024
216.27 B VND
Jan 1, 2025
54.17 B VND
The Imexpharm Operating Cash Flow history
YEAROperating Cash FlowYoY
54.17 BVND-74.95%
216.27 BVND-634.37%
-40.47 BVND-110.69%
378.60 BVND+61.19%
234.88 BVND+221.08%
73.15 BVND+9.86%
66.59 BVND-49.59%
132.09 BVND+35.88%
97.21 BVND+14.84%
84.65 BVND+88.95%
44.80 BVND+187.10%
15.60 BVND—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imexpharm stock

Operating Cash Flow of Imexpharm is 54.17 B VND in 2025.

Operating Cash Flow of Imexpharm changed from 216.27 B VND to 54.17 B VND, representing a -74.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Imexpharm since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's VND is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Imexpharm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Imexpharm

All Key Metrics — Imexpharm